Linked Life Data

15569374

Source:http://linkedlifedata.com/resource/pubmed/id/15569374

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2004-11-30
pubmed:abstractText
Flavopiridol is a synthetic flavone that has shown an antitumor effect against several cancers. Here, we investigated the in vitro effect of flavopiridol alone and the combined effect of low-dose flavopiridol plus radiation on esophageal squamous cell carcinoma cell lines. Esophageal squamous cell carcinoma cell lines (TE8, TE9 and KE4) were exposed to flavopiridol (0.05-400 nmol/L) for 48 h. Growth inhibition was evaluated by MTT assay, cell cycle distribution was determined by flow cytometry, and cyclin D1, Bcl-2 and Rb protein expression was detected by Western blotting. The effect of 0.05 nmol/L flavopiridol as a radio-sensitizer was determined by clonogenic assay. The IC50 was approximately 110-250 nmol/L. Exposure to 0.05 nmol/L flavopiridol for 48 h increased the G2/M population, while 300 nmol/L increased the G1 population. At a concentration of 300 nmol/L, nuclear fragmentation and chromatin condensation were observed in all three cell lines. Exposure to 300 nmol/L flavopiridol decreased the levels of cyclin D1 and Rb protein in all three cell lines and Bcl-2 protein was also decreased in TE8 and KE4 cells. Moreover, exposure to 0.05 nmol/L flavopiridol slightly decreased the levels of cyclin D1, Rb and Bcl-2 protein in KE4 cells. Flavopiridol treatment (0.05 nmol/L) enhanced the radio-sensitivity in all three cell lines. Low-dose flavopiridol augmented the response of esophageal squamous cell carcinoma cell lines to radiation. Administration of a low dose of flavopiridol could be a potent new therapeutic approach for improving the efficacy of radiotherapy against esophageal cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1120-8694
pubmed:author
pubmed:issnType
Print
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
338-44
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15569374-Antineoplastic Agents, pubmed-meshheading:15569374-Apoptosis, pubmed-meshheading:15569374-Blotting, Western, pubmed-meshheading:15569374-Carcinoma, Squamous Cell, pubmed-meshheading:15569374-Cell Cycle, pubmed-meshheading:15569374-Cell Line, Tumor, pubmed-meshheading:15569374-Cell Proliferation, pubmed-meshheading:15569374-Cyclin D1, pubmed-meshheading:15569374-Esophageal Neoplasms, pubmed-meshheading:15569374-Flavonoids, pubmed-meshheading:15569374-Flow Cytometry, pubmed-meshheading:15569374-Formazans, pubmed-meshheading:15569374-Genes, bcl-2, pubmed-meshheading:15569374-Growth Inhibitors, pubmed-meshheading:15569374-Humans, pubmed-meshheading:15569374-Piperidines, pubmed-meshheading:15569374-Radiation Tolerance, pubmed-meshheading:15569374-Radiation-Sensitizing Agents, pubmed-meshheading:15569374-Retinoblastoma Protein, pubmed-meshheading:15569374-Tetrazolium Salts, pubmed-meshheading:15569374-Treatment Outcome
pubmed:year
2004
pubmed:articleTitle
Flavopiridol as a radio-sensitizer for esophageal cancer cell lines.
pubmed:affiliation
First Department of Surgery, Juntendo University School of Medicine, Tokyo, Japan. ssato@maz.miinet.or.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't